Moderna scores Win in Vaccine Patent Showdown

Moderna takes the win in COVID-19 vaccines patent battle.

Ludo Lugnani
Ludo Lugnani

In Short: Moderna just scored a win at the European Patent Office (EPO) in its patent brawl with Pfizer and BioNTech over COVID-19 vaccines.

What's Going On?

Moderna and Pfizer are like heavyweight boxers in the ring, duking it out over who owns the rights to some pretty crucial vaccine technology. Recently, Moderna landed a solid punch—the EPO decided to back one of its key patents, EP949. This patent involves some fancy science about tweaking mRNA to make the vaccine work better without freaking out your immune system.

  • The Claim: Moderna argued Pfizer’s Comirnaty vaccine infringes on its patents. Moderna wanted a share of the profits from Pfizer's COVID-19 vaccine sales.
  • Why Moderna Won: The EPO looked at Moderna's idea, called the EP949 patent, and agreed that it's a real and important invention. The EPO decided that Moderna’s invention is unique and valuable, and Pfizer shouldn't have used it without permission.

Moderna's been claiming that Pfizer’s Comirnaty vaccine is stepping on its patent toes, and this win gives them a leg up in the ongoing fight. But don’t count Pfizer out just yet. They’ve got nine months to appeal this decision, and they probably will. Meanwhile, the legal fireworks are continuing across Europe, with Moderna trying to snag a piece of the big bucks Pfizer made from their vaccine.

What Does This Mean?

For Moderna, this ruling is like finding an extra life in a video game—it's a big deal. It strengthens their position in claiming that Pfizer owes them for using their patented technology. This patent isn’t just about COVID-19 vaccines; it could also be key for future mRNA treatments. So, it’s a win-win for Moderna in the present and the future.

On the other hand, Pfizer and BioNTech aren’t just going to roll over. They’re arguing that Moderna’s patents shouldn’t even be valid in the first place. So, brace yourself for more courtroom drama. It's like a never-ending episode of a legal thriller series, with billions of dollars and the future of vaccine tech on the line.

For now, Moderna’s doing a little victory dance, but the saga continues. The decisions made here will impact not just these companies but the whole biotech industry. It’s a high-stakes game with potential breakthroughs in medicine hanging in the balance. Stay tuned, because this story is far from over and promises plenty more twists and turns!

How does this impact Law Firms?

This post is for paying subscribers only


Already have an account? Log in